Abstract:Purpose: The promising clinical activity of paclitaxel, a naturally occurring antimicrotubule agent, has promoted considerable interest in combining this drug with radiation therapy, but it remains unclear whether such a combination would increase the therapeutic efficacy. This study is to assess the potential interactions between paclitaxel and gamma-radiation against human tumor cells in vitro.Experimental Design: Paclitaxel and gamma-radiation were administered in three different sequences designated as pre-radiated, co-radiated, and post-radiated to BCap37 (human breast cancer cell line) and KB (human epidermoid carcinoma cell line) cells. The cytotoxic interactions between and mutual influences of these two agents on their antitumor activities were analyzed by a series of assays including cytotoxic, morphological, and biochemical examinations.Results: The combination of paclitaxel and gamma-radiation did not produce a synergistic or additive effect. Instead, the overall in vitro cytotoxicity of these combinations was much lower than that of paclitaxel treatment alone. DNA fragmentation and flow cytometric assays showed that the addition of gamma-radiation interfered with paclitaxel-induced apoptosis. Further analyses indicated that the addition of gamma-radiation resulted in a transient or prolonged cell cycle arrest at G(2) phase, which likely prevented the cytotoxic effects of paclitaxel on both mitotic arrest and apoptosis. In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2).Conclusions: Our results suggest that gamma-radiation might specifically block the cell cycle at G(2) phase, which in turn prevents the cytotoxic effects of paclitaxel on both mitotic arrest and apoptosis. Therefore, it eventually results in a cell cycle-dependent antagonistic effect on the antitumor activity of paclitaxel. This finding may be relevant to the clinical application of combination therapy with paclitaxel and radiation.

Inhibition of Nuclear Factor-Κb by an Antioxidant Enhances Paclitaxel Sensitivity in Ovarian Carcinoma Cell Line

Establishment of a new paclitaxel resistant cell line of human ovarian carcinoma and preliminary observation of its biology.

Pyrrolidine dithiocarbamate enhances chemosensitivity of ovarian cancer cells to docetaxel and its machanism

Targeted Inhibition of Transient Activation of the EGFR-mediated Cell Survival Pathway Enhances Paclitaxel-Induced Ovarian Cancer Cell Death

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells

Pyrrolidine dithiocarbamate, a inhibitor of NF- κB, enhances chemosensitivity of ovarian cancer cells to cisplatin

Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells with Acquired Paclitaxel Resistance

AdIκBα transfer reverses the chemoresistance to taxol by inducing apoptosis in nude mice with human non-small cell lung cancer

Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells

Effect of paclitaxel octreotide conjugate on human ovarian paclitaxel-resistant cell xenograft tumor model and the mechanism underlying reversal of paclitaxel resistance

Oxycodone enhances antitumor effect of paclitaxel on human breast cancer SKBR3 cells in vitro

The Relationship Between P38mapk and Apoptosis During Paclitaxel Resistance of Ovarian Cancer Cells

Cell Cycle-Dependent Antagonistic Interactions Between Paclitaxel and Gamma-Radiation in Combination Therapy

Impact of NF-κB on P-glycoprotein-mediated Multidrug Resistance in Ovarian Cancer Cells

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Reversal Effect of Phosphatidylinositol 3'-kinase Inhibitor LY294002 during Chemotherapy on Paclitaxel Resistance of Ovarian Cancer Cell Lines

The Possible Correlation Between Activation of NF-kappaB/IkappaB Pathway and the Susceptibility of Tumor Cells to Paclitaxel-Induced Apoptosis.

Synthetic Paclitaxel-Octreotide Conjugate Reverses the Resistance of Paclitaxel in A2780/Taxol Ovarian Cancer Cell Line

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.

Nuclear Factor-Kappab/ikappab Signaling Pathway May Contribute to the Mediation of Paclitaxel-Induced Apoptosis in Solid Tumor Cells.

Anti-proliferation effect of paclitaxel with the combination of curcumin on human ovarian carcinoma cell line OC3